T1	DISO 951 954	HIV
T2	ANAT 58 71	células madre
#1	AnnotatorNotes T2	C0038250; Stem cells; Cell
T3	ANAT 87 101	tejido adiposo
#2	AnnotatorNotes T3	C0001527; Adipose tissue; Tissue
T4	DISO 119 160	neumonía severa provocada por coronavirus
T5	PROC 183 249	Ensayo clínico Fase I/II, multicéntrico, aleatorizado y controlado
T6	PROC 256 290	valorar la seguridad y la eficacia
#3	AnnotatorNotes T6	C0511730; Identify product efficacy and safety issues; Health Care Activity
T7	PROC 297 323	administración intravenosa
#4	AnnotatorNotes T7	C0455142; Intravenous therapy; Therapeutic or Preventive Procedure
T8	ANAT 327 366	células troncales mesenquimales adultas
T9	ANAT 381 395	tejido adiposo
#5	AnnotatorNotes T9	C0001527; Adipose tissue; Tissue
T10	DISO 424 452	neumonía severa por COVID-19
T11	DISO 476 500	Neumonía por coronavirus
T12	DISO 527 555	Neumonía severa por COVID-19
T13	PROC 599 618	Diagnóstico clínico
#6	AnnotatorNotes T13	C0332140; Diagnosis, clinical; Diagnostic Procedure
T14	DISO 622 630	Neumonía
#7	AnnotatorNotes T14	C0032285; Pneumonia; Disease or Syndrome
T15	DISO 662 684	infección por COVID-19
#8	AnnotatorNotes T15	C5203670; COVID19 (disease); Disease or Syndrome
T16	PROC 766 787	método anticonceptivo
#9	AnnotatorNotes T16	C0700589; Contraceptive methods; Therapeutic or Preventive Procedure
T17	PROC 865 879	ensayo clínico
#10	AnnotatorNotes T17	C0008976; Clinical Trials; Research Activity
T18	DISO 910 921	Coinfección
#11	AnnotatorNotes T18	C0275524; Coinfection; Disease or Syndrome
T19	DISO 956 968	tuberculosis
#12	AnnotatorNotes T19	C0041296; Tuberculosis; Disease or Syndrome
T20	DISO 1006 1031	infecciones respiratorias
#13	AnnotatorNotes T20	C0035243; Respiratory Tract Infections; Disease or Syndrome
T21	DISO 1033 1061	infección activa por VHB o C
T22	DISO 1091 1099	alergias
#14	AnnotatorNotes T22	C1527304; Allergic Reaction; Pathologic Function
T23	CHEM 1141 1153	B-lactámicos
T24	DISO 1112 1119	alergia
#15	AnnotatorNotes T24	C1527304; Allergic Reaction; Pathologic Function
T25	CHEM 1122 1132	penicilina
#16	AnnotatorNotes T25	C0030842; penicillins; Antibiotic · Organic Chemical
T26	DISO 1209 1225	tumores malignos
#17	AnnotatorNotes T26	C0006826; Malignant Neoplasms; Neoplastic Process
T27	DISO 1228 1238	hemopatías
#18	AnnotatorNotes T27	C0018939; Hematological Disease; Disease or Syndrome
T28	DISO 1261 1276	inmunosupresión
#19	AnnotatorNotes T28	C4048329; Immunosuppression; Disease or Syndrome
T29	DISO 1319 1343	enfermedades autoinmunes
#20	AnnotatorNotes T29	C0004364; Autoimmune Diseases; Disease or Syndrome
T30	DISO 1349 1379	Insuficiencia cardíaca crónica
#21	AnnotatorNotes T30	C0264716; Chronic heart failure; Disease or Syndrome
T31	PROC 1384 1404	fracción de eyección
#22	AnnotatorNotes T31	C0489482; Ejection fraction (procedure); Diagnostic Procedure
T32	DISO 976 985	influenza
#23	AnnotatorNotes T32	C0021400; Influenza; Disease or Syndrome
T33	ANAT 1363 1371	cardíaca
#24	AnnotatorNotes T33	C0018787; Heart; Body Part, Organ, or Organ Component | C1281570; Entire heart; Body Part, Organ, or Organ Component
T34	Date 13 17	2020
T35	LIVB 105 114	pacientes
#25	AnnotatorNotes T35	C0030705; Patients; Patient or Disabled Group
T36	LIVB 149 160	coronavirus
#26	AnnotatorNotes T36	C5203676; SARS-CoV-2; Virus
T37	Route 312 323	intravenosa
#27	AnnotatorNotes T37	C1522726; Intravenous Route of Drug Administration; Functional Concept
T39	LIVB 410 419	pacientes
#28	AnnotatorNotes T39	C0030705; Patients; Patient or Disabled Group
T40	LIVB 489 500	coronavirus
#29	AnnotatorNotes T40	C5203676; SARS-CoV-2; Virus
T41	Age 590 594	≥ 18
T42	Duration 709 728	superior a 48 horas
T43	LIVB 817 824	hombres
#30	AnnotatorNotes T43	C0025266; Male population group; Population Group
T44	LIVB 833 840	mujeres
#31	AnnotatorNotes T44	C0043210; Woman; Population Group
T45	LIVB 932 937	virus
#32	AnnotatorNotes T45	C0042776; Virus; Virus
T46	LIVB 940 949	bacterias
#33	AnnotatorNotes T46	C0004611; Bacteria; Bacterium
T48	LIVB 970 985	virus influenza
#34	AnnotatorNotes T48	C4316910; Influenza virus; Virus
T49	LIVB 987 997	adenovirus
#35	AnnotatorNotes T49	C0001483; Adenoviruses; Virus
T50	LIVB 1054 1061	VHB o C
#36	AnnotatorNotes T50	C0019169; Hepatitis B virus; Virus | C0220847; Hepatitis C virus; Virus
T51	LIVB 1158 1177	Mujeres embarazadas
#37	AnnotatorNotes T51	C0033011; Pregnant Women; Population Group
T52	LIVB 1180 1189	lactantes
#38	AnnotatorNotes T52	C4316174; Patients who are breastfeeding; Patient or Disabled Group
T53	LIVB 1195 1204	Pacientes
#39	AnnotatorNotes T53	C0030705; Patients; Patient or Disabled Group
T54	LIVB 1305 1314	Pacientes
#40	AnnotatorNotes T54	C0030705; Patients; Patient or Disabled Group
T55	Duration 1372 1379	crónica
#41	AnnotatorNotes T55	C0205191; chronic; Temporal Concept
T57	LIVB 1476 1498	investigador principal
#42	AnnotatorNotes T57	C1521895; Principal Investigator; Professional or Occupational Group
T58	LIVB 1520 1526	sujeto
#43	AnnotatorNotes T58	C0681850; Study Subject; Group
T61	ANAT 1018 1031	respiratorias
#44	AnnotatorNotes T61	C0035237; Respiratory System; Body System | C1269561; Entire respiratory system; Body System
T63	PHYS 1396 1404	eyección
#45	AnnotatorNotes T63	C2733340; Ventricular ejection; Physiologic Function
T38	PHYS 1166 1177	embarazadas
#46	AnnotatorNotes T38	C0032961; Pregnancy; Organism Function
A1	Status T22 History_of
A2	Status T24 History_of
#47	AnnotatorNotes T5	C1519043; Phase I/II Trial; Research Activity + C1096776; Multicenter Study; Research Activity + C0206035; Controlled Clinical Trials, Randomized; Research Activity
#48	AnnotatorNotes T11	C5419163; COVID-19-Associated Pneumonia; Disease or Syndrome | C5244027; Pneumonia caused by SARS-CoV-2; Disease or Syndrome 
#49	AnnotatorNotes T12	C5400377; COVID-19 pneumonia aggravated; Disease or Syndrome (?)
#50	AnnotatorNotes T1	C2363741; HIV-1 infection; Disease or Syndrome
#51	AnnotatorNotes T8	C5400079; Adult human mesenchymal stem cells; Cell
#52	AnnotatorNotes T21	C0019163; Hepatitis B; Disease or Syndrome + C0019196; Hepatitis C; Disease or Syndrome
#53	AnnotatorNotes T23	C0282215; beta-Lactams; Organic Chemical · Antibiotic 
T47	Observation 1530 1550	se ajusta al estudio
A3	Assertion T47 Negated
#54	AnnotatorNotes T47	C1302261; Patient eligible for clinical trial; Finding (?)
T56	Neg_cue 1527 1529	no
T59	CONC 689 708	Expectativa de vida
#55	AnnotatorNotes T59	C0023671; Life Expectancy; Group Attribute
R1	Has_Duration_or_Interval Arg1:T59 Arg2:T42	
R2	Experiences Arg1:T35 Arg2:T4	
R3	Causes Arg1:T36 Arg2:T4	
#56	AnnotatorNotes T4	C5400377; COVID-19 pneumonia aggravated; Disease or Syndrome (?)
#57	AnnotatorNotes T10	C5400377; COVID-19 pneumonia aggravated; Disease or Syndrome (?)
R4	Causes Arg1:T15 Arg2:T14	
T60	Quantifier_or_Qualifier 72 101	procedentes de tejido adiposo
R5	Has_Quantifier_or_Qualifier Arg1:T2 Arg2:T60	
T62	Quantifier_or_Qualifier 378 406	de tejido adiposo expandidas
R6	Has_Quantifier_or_Qualifier Arg1:T8 Arg2:T62	
R8	Has_Route_or_Mode Arg1:T7 Arg2:T37	
R9	Experiences Arg1:T39 Arg2:T7	
R10	Experiences Arg1:T39 Arg2:T10	
T64	Quantifier_or_Qualifier 367 377	alogénicas
#58	AnnotatorNotes T64	C1515895; Allogeneic; Qualitative Concept
R11	Has_Quantifier_or_Qualifier Arg1:T8 Arg2:T64	
R12	Causes Arg1:T40 Arg2:T11	
T65	Quantifier_or_Qualifier 632 638	severa
#59	AnnotatorNotes T65	C1547227; Severe - Severity of Illness Code; Intellectual Product
R13	Has_Quantifier_or_Qualifier Arg1:T14 Arg2:T65	
R14	Causes Arg1:T25 Arg2:T24	
R15	Causes Arg1:T23 Arg2:T24	
R16	Causes Arg1:T25 Arg2:T22	
R17	Causes Arg1:T23 Arg2:T24	
R18	Location_of Arg1:T61 Arg2:T20	
R19	Causes Arg1:T50 Arg2:T21	
R20	Causes Arg1:T45 Arg2:T18	
R21	Causes Arg1:T46 Arg2:T18	
R22	Causes Arg1:T45 Arg2:T1	
R23	Causes Arg1:T46 Arg2:T19	
R24	Causes Arg1:T48 Arg2:T32	
R25	Causes Arg1:T49 Arg2:T18	
T66	Quantifier_or_Qualifier 788 807	de eficacia probada
R26	Has_Quantifier_or_Qualifier Arg1:T16 Arg2:T66	
R27	Experiences Arg1:T43 Arg2:T16	
R28	Experiences Arg1:T44 Arg2:T16	
R29	Overlap Arg1:T16 Arg2:T17	
T67	Quantifier_or_Qualifier 641 648	crítica
#60	AnnotatorNotes T67	C1511545; Critical; Qualitative Concept 
R30	Has_Quantifier_or_Qualifier Arg1:T14 Arg2:T67	
R31	Causes Arg1:T45 Arg2:T20	
R32	Causes Arg1:T49 Arg2:T20	
R33	Causes Arg1:T46 Arg2:T20	
R34	Experiences Arg1:T51 Arg2:T38	
R35	Experiences Arg1:T53 Arg2:T26	
R36	Experiences Arg1:T53 Arg2:T27	
R37	Experiences Arg1:T53 Arg2:T28	
T68	Quantifier_or_Qualifier 1294 1299	grave
#61	AnnotatorNotes T68	C1547227; Severe - Severity of Illness Code; Intellectual Product
R38	Has_Quantifier_or_Qualifier Arg1:T28 Arg2:T68	
R39	Experiences Arg1:T54 Arg2:T29	
R40	Location_of Arg1:T33 Arg2:T30	
R41	Has_Duration_or_Interval Arg1:T30 Arg2:T55	
T69	Result_or_Value 1405 1420	inferior al 30%
R44	Has_Result_or_Value Arg1:T31 Arg2:T69	
R46	Negation Arg1:T56 Arg2:T47	
A4	Experiencer T52 Patient
A5	Experiencer T51 Patient
A6	Experiencer T53 Patient
A7	Experiencer T54 Patient
A8	Experiencer T57 Other
A9	Experiencer T58 Patient
A10	Experiencer T44 Patient
A11	Experiencer T43 Patient
A12	Experiencer T39 Patient
A13	Experiencer T35 Patient
